Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective

Area of Science:

• Oncology and Pharmacology
• Drug Discovery and Development

Background:

• Histone deacetylase (HDAC) inhibitors modulate gene expression impacting cancer processes like apoptosis and metastasis.
• Current HDAC inhibitors face challenges including adverse effects, therapeutic resistance, and poor pharmacokinetics.
• Multi-targeted agents offer synergistic therapeutic potential for complex diseases like cancer.

Approach:

• Designing dual/multi-target HDAC inhibitors is a key strategy to mitigate side effects and drug resistance.
• Target combinations are identified through high-throughput screening (HTS) and network pharmacology.
• Pharmacophores are identified using computational methods and linked to create multi-functional inhibitors.

Key Points:

• HDAC inhibitors affect multiple cellular pathways, leading to adverse effects and resistance.
• Combining HDAC inhibition with other targets can enhance anticancer activity and overcome limitations.
• Strategies involve merging, fusing, or linking pharmacophores to interact with multiple targets.

Conclusions:

• Dual/multi-targeting HDAC inhibitors represent a promising approach for more effective cancer treatment.
• This strategy aims to improve efficacy, reduce side effects, and overcome drug resistance in cancer therapy.
• Further development of these inhibitors is crucial for advancing cancer treatment paradigms.